


On the Horizon Rx

a Humana Healthy Horizons
newsletter for pharmacy providers

Volume IV



Updates made to the Preferred Drug List

Based on recommendations by the Florida Pharmaceutical & Therapeutics Committee, the Agency for Health Care Administration (AHCA) establishes and maintains the Florida Medicaid Preferred Drug List (PDL). The committee met on Sept. 23, 2022, and approved changes to the PDL that went into effect for Humana Healthy Horizons® in Florida members on Dec. 8, 2022. Members were notified 30 days before the effective date.

Drug name	PDL status before meeting	PDL status after meeting	Comment
ALZHEIMER'S AGENTS			
ADLARITY (TRANSDERM)	N/A	Non-PDL	
ANALGESICS, NARCOTICS SHORT			
OXYCODONE / APAP SOLUTION (ORAL)	PDL	Non-PDL	
ANTICONSULTANTS			
LACOSAMIDE SOLUTION (ORAL)	Non-PDL	PDL	
LACOSAMIDE TABLET (ORAL)	Non-PDL	PDL	
VIGABATRIN TABLET (ORAL)	PDL	Non-PDL	
VIMPAT SOLUTION (ORAL)	PDL	Non-PDL	
VIMPAT TABLET (ORAL)	PDL	Non-PDL	
ANTIDOTE CHELATING AGENTS			
DEFERASIROX (JADENU) (ORAL)	Non-PDL	PDL	
ANTIFUNGALS, ORAL			
BREXAFEMME (ORAL)	N/A	Non-PDL	

Humana
Healthy Horizons®
in Florida

Humana Healthy Horizons in Florida is a Medicaid product of Humana Medical Plan Inc.

FLHLVR6EN0123

Drug name	PDL status before meeting	PDL status after meeting	Comment
ANTIHISTAMINES, MINIMALLY SEDATING			
DESLORATADINE (ORAL)	N/A	Non-PDL	
ANTIMIGRAINE AGENTS, TRIPTANS			
IMITREX (NASAL)	Non-PDL	PDL	
ANTIPRURITICS, TOPICAL			
ZONALON (TOPICAL)	Non-PDL	PDL	Auto-PA
ANTIPSYCHOTICS			
INVEGA HAFYERA (INTRAMUSCULAR)	Non-PDL	PDL	Auto-PA
PERSERIS (SUBCUTANEOUS)	Non-PDL	PDL	Auto-PA
ANTIVIRALS, GENERAL			
LIVTENCITY (ORAL)	N/A	Non-PDL	
VALCYTE SOLUTION (ORAL)	Non-PDL	PDL	
BONE RESORPTION SUPPRESSION AND RELATED AGENTS			
RALOXIFENE (ORAL)	Non-PDL	PDL	
GI MOTILITY, CHRONIC			
IBSRELA (ORAL)	N/A	Non-PDL	
HYPERPARATHYROID AGENTS			
CINACALCET (ORAL)	Non-PDL	PDL	
HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS			
MOUNJARO (SUBCUTANEOUS)	N/A	Non-PDL	
LAXATIVES & CATHARTICS			
MOVIPREP POWDER PACK (ORAL)	Non-PDL	PDL	
MACULAR DEGENERATION AGENTS			
BYOOVIZ VIAL (INTRAOCULAR)	N/A	Non-PDL	
VABYSMO VIAL (INTRAOCULAR)	N/A	Non-PDL	
NEUROPATHIC PAIN			
NEURONTIN CAPSULE (ORAL)	PDL	Non-PDL	
NEURONTIN SOLUTION (ORAL)	PDL	Non-PDL	
NEURONTIN TABLET (ORAL)	PDL	Non-PDL	
NSAIDS			
INDOMETHACIN CAPSULE ER (ORAL)	Non-PDL	PDL	
NAPROXEN SODIUM (ORAL)	Non-PDL	PDL	
PIROXICAM (ORAL)	Non-PDL	PDL	
SULINDAC (ORAL)	Non-PDL	PDL	
NSAIDS, INJECTABLE			
ANJESO (INTRAVENOUS)	PDL	Non-PDL	
CALDOLOR (INTRAVENOUS)	Non-PDL	PDL	
ONCOLOGY, ORAL – BREAST			
VERZENIO (ORAL)	Non-PDL	PDL	

Drug name	PDL status before meeting	PDL status after meeting	Comment
ONCOLOGY, ORAL – HEMATOLOGIC			
LENALIDOMIDE (ORAL)	PDL	Non-PDL	
POMALYST (ORAL)	PDL	Non-PDL	
SCEMBLIX (ORAL)	N/A	Non-PDL	
TABLOID (ORAL)	Non-PDL	PDL	
VENCLEXTA (ORAL)	Non-PDL	PDL	
VONJO (ORAL)	N/A	Non-PDL	
ONCOLOGY, ORAL – LUNG			
EXKIVITY (ORAL)	N/A	Non-PDL	
IRESSA (ORAL)	PDL	Non-PDL	
ONCOLOGY, ORAL – RENAL CELL			
SUNITINIB (ORAL)	PDL	Non-PDL	
SUTENT (ORAL)	Non-PDL	PDL	
WELIREG (ORAL)	N/A	Non-PDL	
ONCOLOGY, ORAL - SKIN			
MEKINIST (ORAL)	Non-PDL	PDL	
TAFINLAR (ORAL)	Non-PDL	PDL	
OPHTHALMIC ANTIBIOTIC-STEROID COMBINATIONS			
TOBRADEX ST (OPHTHALMIC)	Non-PDL	PDL	
OPHTHALMICS, ANTI-INFLAMMATORIES			
ILEVRO (OPHTHALMIC)	N/A	Non-PDL	
OPHTHALMICS, ANTI-INFLAMMATORY/IMMUNOMODULATOR			
TYRVAYA SPRAY (NASAL)	N/A	Non-PDL	
OPIATE DEPENDENCE TREATMENTS			
ZIMHI (INJECTION)	N/A	Non-PDL	
PAH AGENTS, ORAL AND INHALED			
TYVASO DPI (INHALATION)	N/A	Non-PDL	
PITUITARY SUPPRESSIVE AGENTS, LHRH			
CAMCEVI (SUBCUTANEOUS)	N/A	Non-PDL	
SEDATIVE HYPNOTICS			
QUVIVIQ (ORAL)	N/A	Non-PDL	
SKELETAL MUSCLE RELAXANTS			
LYVISPAAH (ORAL)	N/A	Non-PDL	
N/A = Not applicable (for new products)			



COVID-19 at-home tests, treatment, and vaccine update

Humana Healthy Horizons covers all at-home COVID-19 testing kits. The patient can administer these tests to detect current COVID-19 infections. At-home tests do not detect COVID-19 antibodies or previous infections. Members have a \$0 copay for these at-home testing kits.

The U.S. Food and Drug Administration (FDA) authorized certain antiviral medications and monoclonal antibodies to treat mild to moderate COVID-19 in people who are more likely to get very sick. Pharmacists have been granted the ability to prescribe Paxlovid to certain patients under an emergency use authorization.

The FDA granted emergency use authorization to the following antiviral COVID-19 treatments:

- Paxlovid (nirmatrelvir/ritonavir) for people 12 years and older (oral)
- Lagevrio (molnupiravir) for people 18 years and older (oral)
- Veklury (remdesivir) for people 28 days and older (intravenous infusion)

The FDA granted emergency use authorization to the following monoclonal antibody COVID-19 treatments:

- Bebtelovimab for people 12 years and older (intravenous injection)

According to the **Centers for Disease Control and Prevention (CDC)**, COVID-19 vaccination is recommended for all people 6 months and older, including people who are pregnant, breastfeeding, trying to get pregnant now or might become pregnant.

The FDA granted full use authorization to the following COVID-19 vaccines:

- The Pfizer-BioNTech (Comirnaty) COVID-19 vaccine for people 16 years and older
- The Moderna (Spikevax) COVID-19 vaccine for people 12 years and older

The FDA granted emergency use authorization to the following COVID-19 vaccines:

- The Pfizer-BioNTech COVID-19 vaccine for people 6 months and older
- The Moderna COVID-19 vaccine for people 6 months and older
- The Novavax COVID-19 vaccine for people 12 years and older
- The Johnson & Johnson (Janssen) vaccine for people 18 years and older

The FDA granted emergency use authorization to the following bivalent COVID-19 vaccines, which protect against the original virus and the Omicron variants BA.4 and BA.5:

- The Pfizer-BioNTech COVID-19 bivalent vaccine for people aged 5 years and older
- The Moderna COVID-19 bivalent vaccine for people 6 years and older

As a reminder, Florida members can receive a COVID vaccine at all in-network pharmacies or providers. At this time, Humana does not prefer one vaccine product over another.

Please encourage members 5 years and older to get vaccinated. While cases of myocarditis and pericarditis in adolescents and young adults have been reported more often after the second dose than the first dose of the Pfizer-BioNTech and Moderna vaccines, these reports are rare, and the known and potential benefits of vaccination outweigh known and potential risks. You can locate more information and learn how to report adverse events at the CDC website's article, titled **Selected Adverse Events Reported after COVID-19 Vaccination**.



HEDIS measures related to diabetes care

Pharmacists can be instrumental in helping patients manage diabetes. Pharmacists may provide ongoing education about lifestyle changes, medications and disease state management. They can act as drug therapy experts, encouraging medication compliance and providing medication reconciliation following hospital admissions. Well-controlled diabetes can prevent long-term complications.

According to the CDC, diabetes is the most expensive chronic condition in the U.S.¹:

- \$1 out of every \$4 in U.S. healthcare costs goes toward diabetes care.
- \$237 billion is spent each year on direct medical costs.
- \$90 billion is spent on reduced productivity.
- 48%–64% of lifetime medical costs for a person with diabetes are for complications related to diabetes, such as heart disease and stroke.

Through its accreditation with **National Committee for Quality Assurance (NCQA)**, Humana strives to improve healthcare quality and measurement. To prevent complications in people with diabetes, enhance their quality of life and improve clinical outcomes, Humana measures clinical performance and consumer experience using Health Effectiveness Data and Information Set (HEDIS®) and Consumer Assessment of Healthcare Providers and Systems (CAHPS) data to analyze gaps and guide improvement interventions.

HEDIS measures that relate to care of the diabetic patient include²:

1. Hemoglobin A1c control for patients with diabetes (HBD) 18-75 years old. Goal: HbA1C less than 8% (most recent of measurement year)
2. Blood pressure control for patients with diabetes (BPD) 18-75 years old. Goal: blood pressure less than 140/90 mm Hg (most recent of measurement year)
3. Eye exam for patients with diabetes (EED) 18-75 years old. Goal: diabetic retinal eye exam
4. Kidney health evaluation for patients with diabetes (KED) 18-85 years old. Goal: kidney health evaluation (complete eGFR and uACR)
5. Statin therapy for patients with diabetes (SPD) 40-75 years old (who do not have atherosclerotic cardiovascular disease [ASCVD]). Goal: receive statin therapy (patients who were dispensed at least one statin medication of any intensity during the measurement year) and have statin adherence of 80%



Patients may need help with medication adherence

Humana Pharmacy Solutions® calculates both proportion of days covered (PDC) and the associated percentages to determine medication adherence. PDC ranges from 0–1 with a value of 1 corresponding to 100% adherence. This metric defines acceptable adherence as more than 0.8 (80%) of days covered.

$$\text{PDC} = \frac{\text{Number of days in period "covered"}}{\text{Number of days in period}}$$

The latest metrics from October 2022 show our diabetes adherence remained steady at 0.78 across membership. Our goal is a PDC of 0.8.

Please continue to counsel Humana Healthy Horizons-covered patients on the importance of adherence with respect to meeting their therapeutic goals. Your assistance in monitoring members and making clear to them the importance of medication adherence is key.




2023 preferred blood glucose meters and strips

As of Jan. 1, 2023, Humana prefers Trividia blood glucose meters and strips for Humana Healthy Horizons in Florida-covered patients.

The Trividia preferred meters and strips include:

- True Metrix Blood Glucose Meter
- True Metrix Air Blood Glucose Meter (Bluetooth capability)
- True Metrix Blood Glucose Test Strips

Members can visit **Trividia's website** to view training videos or call the Trividia Customer Care Team at **800-803-6025** if they need help using the new blood glucose meter.



Specialty programs aim to reduce costs

Humana has several specialty programs that promote high-quality care and decrease costs of specialty medications for our members.

The Multidisciplinary Taskforce utilizes a team of Humana associates to influence specialty medication use for rare diseases via thorough case review with the goal of improving patient outcomes and reducing spend.

Utilization management retrospectively identifies opportunities to cut specialty medication waste and costs through consolidating dosage forms, switching to lower-cost generics or optimizing dose frequencies. Pharmacists fax the member's provider to request a new, cost-saving prescription once an opportunity is identified.

The Oncology Specialty Program utilizes pharmacists, including those with board certification in oncology pharmacotherapy, to drive clinical best practices and offer innovative solutions to address the burden of cancer therapy. For example, one program recommends switching from monthly zoledronic acid to every three months in select members based on National Comprehensive Cancer Network guideline recommendations.



Claims data reviewed to help detect adverse utilization

Humana Healthy Horizons' Retrospective Drug Utilization Review Program supports you in the care of your patients through regular reviews of pharmacy claims data to help detect potentially adverse utilization patterns. You may receive subsequent intervention recommendations via direct mail or fax to alert you to important drug safety issues for your patients. Examples of such new campaigns include:

- Asthma inhaled therapy: Prescribers of patients younger than 12 years with an asthma diagnosis, who receive an inhaled corticosteroid without a short-acting bronchodilator may be notified.
- Concurrent opioid and gabapentinoid utilizers: Prescribers of patients with claims for concurrent opioid and high dose gabapentinoid therapy (gabapentin dose more than 900 mg/day or pregabalin dose more than 450 mg/day) may be notified.



SAMHSA removes opioid use disorder prescribing requirement

Early this year, the Substance Abuse and Mental Health Services Administration (SAMHSA) announced it would no longer require nor accept applications for the DATA 2000 waiver previously needed to prescribe the drug most frequently used for the treatment of opioid use disorder (OUD).

All practitioners with a current Drug Enforcement Administration registration that includes prescribing authority for Schedule III substances may now prescribe buprenorphine for OUD if permitted in the state where they practice. The Consolidated Appropriations Act, 2023 (also known as the Omnibus bill) removes the federal requirement for practitioners to submit a Notice of Intent to prescribe medications for the treatment of OUD. This change took effect immediately.



Clinical safety alerts in the pipeline

Humana Healthy Horizons implements concurrent reviews or safety alerts, including various opioid therapy alerts, at the point of service to assist pharmacies in identifying and addressing potentially inappropriate or unsafe drug therapy before dispensing. Your patients may experience medication claims rejections at their pharmacy if they are impacted. For more on Humana Healthy Horizons' point of sale safety updates, please visit the **Controlled Substances - Drug Utilization Review (DUR) webpage**.



Pharmacy references

Agency for Health Care Administration (AHCA) Common PDL quick reference

The AHCA pharmacy team develops and maintains a reference document called the **Florida Medicaid Preferred Drug List (PDL)**. This quick reference was developed for both prescribers and internal care teams to outline the most prescribed medications along with less expensive alternatives. The common PDL receives updates quarterly to align with AHCA's Prescription Drug List changes.

Updated prior authorization criteria

The Florida Drug Utilization Review board recommends new criteria or updates to previous prior authorization criteria as it monitors trends in utilization or as new drugs come to market. AHCA maintains a list of all Pharmacy & Therapeutic-approved drug criteria on its website for your reference.

Plan preferred brands

Medications on this list have both brand and generic formulations. When prescribed to Florida Medicaid recipients, the **brand-name** formulation must be dispensed because of agency rebate agreements. Please help ensure healthcare providers are aware of this requirement, as it has a significant effect on the cost of medication. The pharmacy team is happy to help recommend a lower-cost alternative to these medications when necessary.

Summary of drug limitations

Medications on this list are subject to the corresponding age or quantity limitations. A prior authorization is necessary if these limitations prevent payment of claims at the pharmacy.

General pharmacy news

Find pharmacy-related safety alerts, drug recall and new generic drug announcements and other medication information.

References

1. "Health and Economic Benefits of Diabetes Interventions," National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP), last accessed Jan. 4, 2023, <https://www.cdc.gov/chronicdisease/programs-impact/pop/diabetes.htm>
2. "Evaluation of an Academic-Community Partnership to Implement MTM Services in Rural Communities to Improve Pharmaceutical Care for Patients with Diabetes and/or Hypertension," last accessed Jan. 4, 2023, <https://www.jmcp.org/doi/10.18553/jmcp.2018.24.2.132>